Durvalumab is a medication used in cancer treatment, specifically designed to help the immune system recognize and attack cancer cells. It belongs to a class of drugs known as immune checkpoint inhibitors, which work by blocking proteins that prevent immune responses against tumors. This drug is primarily used for patients with certain types of lung cancer, such as non-small cell lung cancer, and bladder cancer. By enhancing the body's immune response, Durvalumab aims to improve survival rates and overall outcomes for patients undergoing cancer therapy.